MAY 11, 2017 07:30 AM PDT

Keynote Presentation: Genomics in the clinic: A revolution for healthcare and medical research

C.E. CREDITS: CEU | P.A.C.E. CE | Florida CE
  • Head, Kinghorn Centre for Clinical Genomics, Garvan Institute; CEO, Genome.One
      Marcel Dinger is the Founding CEO of Genome.One, Head of the Kinghorn Centre for Clinical Genomics (KCCG) at the Garvan Institute of Medical Research and conjoint Associate Professor at UNSW Australia. Genome.One is a world-class clinical genomics service and develops specialist software and analytics solutions to enable precision healthcare worldwide. Genome.One was one of the first companies in the world to implement the HiSeq X Ten genome sequencing platform, which has capacity to sequence 18,000 human genomes per year, and provide a disease diagnostics service based on whole genome sequencing. He has worked in bioinformatics and genomics since 1998 in both commercial and academic capacities. He was awarded his PhD in 2003 from the University of Waikato in New Zealand, has published >90 papers attracting more than 10,000 citations, and is recipient of several highly competitive awards and fellowships. He is also a founder of two other successful start-up companies. In 2016, Marcel was admitted as a Fellow into the Faculty of Sciences of the Royal College of Pathologists of Australiasia and is a Graduate of the Australian Institute of Company Directors.


    Genetic testing currently plays a relatively niche role in healthcare, with testing typically limited to single genes and targeting a relatively narrow range of diseases, including paediatric disorders, familial cancer and somatic cancer. Recent years has seen exponential decreases in costs of massively parallel DNA sequencing technology, which has dramatically expanded the potential application for genetic testing of other diseases. The Garvan Institute’s Kinghorn Centre for Clinical Genomics was one of the first sites in the world to acquire technology to sequence whole human genomes at scale. The facility now routinely sequences over 1,000 human genomes per month and is NATA-accredited for diagnostic testing of genetic disease. In addition to serving as a highly effective approach for diagnosing diseases that can be caused by large numbers of different genes, whole genome sequencing has potential for reanalysis in different contexts. This potential argues for a new testing paradigm, where genomic sequencing is undertaken once in an individual’s lifetime and analysed throughout their lifetime to guide clinical decision-making and optimise health management. Here I will present on our implementation, clinical accreditation and performance of whole genome sequencing in the routine diagnosis of genetic and rare diseases, and discuss the challenges and opportunities for using genomic information to inform whole of life healthcare.

    Show Resources
    Loading Comments...